Absence of withdrawal effects of ritanserin following chronic dosing in healthy volunteers.
The possible development of withdrawal symptoms following abrupt discontinuation of ritanserin after chronic administration of 10 mg daily for 8 weeks was investigated in a placebo controlled trial in 40 healthy subjects. The study consisted of two phases. In the first phase, under single blind conditions, all subjects received placebo for 2 weeks followed by a single daily dose of ritanserin (10 mg) for 8 weeks. In the second phase, under double blind conditions, subjects were randomised to receive either placebo or to continue on ritanserin (10 mg) for a further 4 weeks. Psychological assessments were performed at the start of and at intervals throughout the study. Levels of anxiety, concentration, quality of sleep and morning vigilance were measured throughout by daily visual analogue scales. No significant changes were detected in any of the measures in the group of subjects who received ritanserin compared to the group who received placebo during the second phase of the study. Ritanserin discontinuation following chronic dosing in healthy volunteers does not appear to be associated with withdrawal symptoms.
Kamali
F
F
Department of Pharmacological Sciences, University of Newcastle upon Tyne, UK.
Stansfield
S C
SC
Ashton
C H
CH
Hammond
G L
GL
Emanuel
M B
MB
Rawlins
M D
MD
D000293:Adolescent; D000328:Adult; D001007:Anxiety / Q000523:psychology; D003863:Depression / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D016713:Ritanserin; D016037:Single-Blind Method; D012890:Sleep / Q000187:drug effects; D013375:Substance Withdrawal Syndrome / Q000523:psychology*
D016713:Ritanserin